logo
Radio signals from the dawn of time could help 'weigh' the universe's 1st stars

Radio signals from the dawn of time could help 'weigh' the universe's 1st stars

Yahoo25-06-2025
When you buy through links on our articles, Future and its syndication partners may earn a commission.
Astronomers could use specific radio signals from the universe's earliest epoch to "weigh" the first stars in the cosmos. The investigation could reveal more about the so-called Cosmic Dawn, the period of the universe during which darkness lifted and light became free to travel.These first stars, or "Population III" (Pop III) stars, can't be seen even with the most powerful telescopes because their light was prevented from traveling by a dense cosmic fog spread between star-forming regions that consisted mostly of hydrogen.
However, during this period, around 100 million years after the Big Bang, this hydrogen created a radio signal called "the 21-centimeter signal." An international team of astronomers now suggests this signal could be used to determine how light from the first stars interacted with this cosmic fog, helping to lift it.
"This is a unique opportunity to learn how the universe's first light emerged from the darkness," team leader and University of Cambridge researcher Anastasia Fialkov said in a statement. "The transition from a cold, dark universe to one filled with stars is a story we're only beginning to understand."
Fialkov heads up the Radio Experiment for the Analysis of Cosmic Hydrogen (REACH) project, a radio antenna that studies the faint glow of the 21-centimeter signal to reveal more about Cosmic Dawn.
Still in its calibration stage, REACH will soon be joined in its investigation of the first stars by the Square Kilometre Array (SKA), a massive array of antennas under construction in Australia and South Africa. Together, SKA and REACH will investigate the masses, luminosities, and distribution of the universe's earliest stars.
In preparation for this investigation, Fialkov and colleagues developed a model to predict what observations of the 21-centimeter signal will look like for both projects. This revealed that this signal is influenced by stellar masses.
"We are the first group to consistently model the dependence of the 21-centimeter signal of the masses of the first stars, including the impact of ultraviolet starlight and X-ray emissions from X-ray binaries produced when the first stars die," said Fialkov. "These insights are derived from simulations that integrate the primordial conditions of the universe, such as the hydrogen-helium composition produced by the Big Bang."
While developing the model, the team studied how the mass distribution of Pop III stars influenced the 21-centimeter signal.
This revealed that the connection between this signal and the first stars has been underestimated in prior research because these studies had failed to account for the number of systems composed of a dense dead star, usually a white dwarf, and an ordinary star, so-called "X-ray binaries" among Pop III stars.
"The predictions we are reporting have huge implications for our understanding of the nature of the very first stars in the universe," REACH telescope Principal Investigator Eloy de Lera Acedo said. "We show evidence that our radio telescopes can tell us details about the mass of those first stars and how these early lights may have been very different from today's stars."
Related Stories:
— How the Rubin observatory could detect thousands of 'failed stars'
— Tiny 'primordial' black holes created in the Big Bang may have rapidly grown to supermassive sizes
— Could dark matter have been forged in a 'Dark Big Bang?'
— Astronomers discover ultrapowerful black hole jet as bright as 10 trillion suns lit by Big Bang's afterglow
REACH and SKA won't see these first stars as a telescope like the James Webb Space Telescope (JWST) does. They instead rely on scientists performing statistical analysis of the data they provide. The effort can pay dividends as it provides information about entire populations of stars, X-ray binary systems and galaxies.
"It takes a bit of imagination to connect radio data to the story of the first stars, but the implications are profound," Fialkov concluded.
The team's research was published on Friday (June 20) in the journal Nature Astronomy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Yahoo

timean hour ago

  • Yahoo

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Douglas E. Williams, Ph.D. Strong track record at executive and board level of building company value across all stages of development including supporting the development of multiple blockbuster medicines Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics ('Draig'), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO). Dr Williams brings more than 30 years of experience in the biopharmaceutical sector, having held executive leadership and board roles across some of the industry's most innovative companies including Biogen, ZymoGenetics, Amgen and Seattle Genetics and contributed to the development of several blockbusters therapies, including Enbrel®, Tecfidera® and Spinraza®. Ruth McKernan, Interim CEO and founder of Draig Therapeutics, said, 'Douglas's exceptional track record of developing innovative therapies and driving strategic growth makes him an ideal leader for our Board. I could not be more delighted. The Company looks forward to benefitting from his leadership and guidance in delivering transformative neuropsychiatric therapies.' 'I am honoured to take on the role of Chair as Draig Therapeutics advances its exciting pipeline into the next phases of clinical development,' said Douglas E. Williams, incoming Chair of Draig Therapeutics. 'More effective therapies for major depressive disorder and other neuropsychiatric disorders remain significant unmet needs for millions of people worldwide. Draig's scientific approach to develop novel medicines for these patients is both compelling and differentiated, and I look forward to working closely with the board and its exceptional leadership team to support the Company achieve its goals.' Most recently, Dr Williams served as the President of R&D at Sana Biotechnology, a leading cell therapy company. Prior to joining Sana, he was the founding CEO of Codiak Biosciences, where he led the company through several private financing rounds as well as a successful initial public offering. Previously, Dr Williams was Executive Vice President (EVP) of Research and Development at Biogen where he played a key role in advancing multiple programmes. Before joining Biogen, he was CEO and a board member at ZymoGenetics, where he led the company through its acquisition by Bristol Myers Squibb in 2010. Earlier in his career, Dr Williams held senior leadership roles at several prominent biotech companies, including Chief Scientific Officer and EVP R&D at Seattle Genetics (Seagen, acquired by Pfizer in 2023 for $43 billion), and Senior VP and Washington Site Leader at Amgen. He spent over a decade at Immunex, where he served as EVP and Chief Technology Officer, and was a member of the Board of Directors. Dr Williams currently serves on the boards of numerous biotechnology companies, including Climb Bio (Chair) and CAMP4 Therapeutics, eGenesis and Stablix (Director). He has also previously been Chair or Director on the boards of multiple private and public companies in the US and Europe over the past 30 years, including CytoImmune Therapeutics, Xenikos, Array Biopharma, AC Immune, Ovid Therapeutics, Ironwood Pharmaceuticals and Regulus Therapeutics, among others. ENDS For further information: Mark Swallow, Sandi GreenwoodE-mail: draigtx@ Draig TherapeuticsE-mail: rmckernan@ About Draig TherapeuticsDraig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders' unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD). Draig is the Welsh word for 'dragon' and it reflects the company's origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University. Draig was co-founded by Cardiff University and SV Health Investors, which led the seed financing with ICG, and is backed by other leading healthcare venture firms including Access Biotechnology, Canaan Partners, SR One, Sanofi Ventures and Schroders Capital. For more information, please visit Attachment Douglas E. Williams, Ph.D. Sign in to access your portfolio

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

Yahoo

timean hour ago

  • Yahoo

AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. "With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis." "We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step." "We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area." AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties. About AATec Medical AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit and follow AATec on LinkedIn. About Northway Biotech Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit Northway Biotech Contact: Prof. Vladas Algirdas BumelisCEO and Chairman of the AATec Medical Contact: Dr. Rüdiger Jankowsky, CEOinfo@ Media Contact: MC ServicesKatja Arnold, Julia von Hummelaatec-medical@ Phone: +49 (0)89 2102280 SOURCE: Northway Biotech View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs
Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs

Yahoo

time2 hours ago

  • Yahoo

Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs

BILBAO, Spain, July 15, 2025--(BUSINESS WIRE)--Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU's Horizon Europe 2021-2027 Research and Innovation Program. As part of this highly competitive program, Oncomatryx will receive €2.5 million in grant funding, along with a €10 million equity investment in its upcoming financing round. The EIC Accelerator call attracted 959 applications, with only 40 companies selected across 16 countries. Oncomatryx is proud to be the only oncology company among this distinguished group. "Securing EIC Accelerator funding is a major milestone for Oncomatryx and a strong validation of our innovative approach to oncology drug development," said Laureano Simón, CEO of Oncomatryx. "This funding will enable us to advance the expansion cohorts of our ongoing Phase I clinical trial in pancreatic, colorectal, and lung cancer, following highly promising results in the dose-escalation phase. We are honored to be recognized as Europe's leading ADC platform and contribute to advancing new treatment options for patients with hard-to-treat solid tumors." Oncomatryx's unique ADC platform integrates proprietary novel payloads and advanced conjugation formats. With fully integrated R&D, chemistry, and conjugation facilities, Oncomatryx stands out as Europe's most advanced ADC development platform, from discovery through to clinical-stage development. The company's novel approach combines a deep understanding of the tumor microenvironment biology with proprietary payloads and linker technologies, positioning Oncomatryx as a strategic leader in oncology innovation. Oncomatryx is currently advancing its lead ADC candidate, OMTX705, in clinical trials targeting Fibroblast Activation Protein in aggressive tumors with high unmet medical need. Encouraging clinical data have been presented at ASCO 2025 meeting. Ninety five patients were treated in the dose escalation and 3 backfilling cohorts of metastatic immune-cold solid tumors. An outstanding safety profile, with no dose limiting toxicity was shown, as well as long responses in patients expressing FAP. Randomized clinical trials are ongoing in immune-cold metastatic pancreatic, MSS colorectal and non-small cell lung cancer. In addition to this recognition from the European Union, Oncomatryx has been designated a strategic company by both the Government of Spain and the Basque Regional Government. The Spanish government R&D funding body, CDTI through Innvierte co-investment initiative for strategic companies and the Basque Regional Government have both invested directly in Oncomatryx, acknowledging its pivotal role in advancing oncology innovation. Together with the EIC Accelerator award, these endorsements firmly position Oncomatryx as a european leading player in Oncology and the ADC field." View source version on Contacts ONCOMATRYX BIOPHARMA, Esnaolaadmin@ DERIO, Spain Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store